Athenex, a US-China Biopharma, Starts US Trial of Oral Chemotherapy

Athenex, a New York State-Hong Kong biopharma, was approved to start a US Phase I trial of its oral regimen of a generic chemotherapy. The trial will combine Athenex's oral topotecan and a proprietary P-glycoprotein (P-gp) inhibitor (HM30181A) that facilitates oral absorption of chemotherapies. Athenex acquired ex-Korea rights to HM30181A from Korea's Hanmi Pharma. Much of the development work for the regimen was carried out in a collaboration between Athenex and The Hong Kong Polytechnic University. More details..., Stock Symbol: (KRX: 128940) Share this with colleagues: // //